Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0F470
|
||||
Drug Name |
FP-025
|
||||
Indication | Asthma [ICD9: 493; ICD10:J45] | Phase 1 | [1] | ||
Target and Pathway | |||||
Target(s) | MMP-12 | Target Info | Inhibitor | [2] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
IL5 Signaling Pathway | |||||
Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
Reactome | Collagen degradation | ||||
Degradation of the extracellular matrix | |||||
WikiPathways | TGF beta Signaling Pathway | ||||
Degradation of collagen | |||||
Matrix Metalloproteinases | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02238834) Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers | ||||
REF 2 | Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.